ARTICLE | Emerging Company Profile

Targeted disruption

PEP-Therapy's peptides block specific protein-protein interactions

November 2, 2015 8:00 AM UTC

PEP-Therapy S.A.S. is developing fusion peptides for cancer that block specific intracellular protein-protein interactions, which could be safer than broad inhibitors of the same proteins.

The company's fusion peptides comprise an optimized cell-penetrating peptide that shuttles a short interfering peptide into the cell...